ER negative
|
Breast Cancer
|
ER negative
|
Breast Cancer
|
toremifene Resistant: A1 - Approval
|
toremifene Resistant: A1 - Approval
|
ER negative
|
Breast Cancer
|
ER negative
|
Breast Cancer
|
anastrozole Sensitive: A1 - Approval
|
anastrozole Sensitive: A1 - Approval
|
ER negative
|
HER2 Positive Breast Cancer
|
ER negative
|
HER2 Positive Breast Cancer
|
pertuzumab + Herzuma (trastuzumab biosimilar) Sensitive: C3 – Early Trials
|
pertuzumab + Herzuma (trastuzumab biosimilar) Sensitive: C3 – Early Trials
|
ER negative
|
HER2 Positive Breast Cancer
|
ER negative
|
HER2 Positive Breast Cancer
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
ER negative
|
Breast Cancer
|
ER negative
|
Breast Cancer
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
ER negative
|
HER2 Positive Breast Cancer
|
ER negative
|
HER2 Positive Breast Cancer
|
TCHP Sensitive: C3 – Early Trials
|
TCHP Sensitive: C3 – Early Trials
|
ER negative
|
HER2 Negative Breast Cancer
|
ER negative
|
HER2 Negative Breast Cancer
|
doxorubicin hydrochloride Resistant: D – Preclinical
|
doxorubicin hydrochloride Resistant: D – Preclinical
|
ER negative
|
HER2 Negative Breast Cancer
|
ER negative
|
HER2 Negative Breast Cancer
|
docetaxel Resistant: D – Preclinical
|
docetaxel Resistant: D – Preclinical
|
ER negative
|
HER2 Positive Breast Cancer
|
ER negative
|
HER2 Positive Breast Cancer
|
doxorubicin hydrochloride Resistant: D – Preclinical
|
doxorubicin hydrochloride Resistant: D – Preclinical
|
ER negative
|
HER2 Positive Breast Cancer
|
ER negative
|
HER2 Positive Breast Cancer
|
docetaxel Resistant: D – Preclinical
|
docetaxel Resistant: D – Preclinical
|